Skip to main content
OpenTrials
Completed

NCT Number: NCT02787616

Genetic Basis of Rosacea

Rosacea is a common disease characterized by inflammation and vascular abnormalities of the facial skin and ocular surface. The exact pathogenesis of papulopustular rosacea is not well understood and current methods to treat this disease are often unsatisfactory. The purpose of this study is to develop gene expression profiles of papulopustular rosacea compared to those of normal skin. The investigators hope to better understand the abnormal gene functions that might contribute to this condition. This understanding may lead to the development of additional and better treatments for rosacea.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Stanford Dermatology

Redwood City, California, 94603, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Eligibility Criteria for Rosacea Group:

Inclusion criteria

for rosacea participants:

  • Clinical signs and symptoms of rosacea (papulopustular or erythrotelangiectatic subtypes) present at enrollment as determined by the investigator
  • All four grandparents of European descent
  • Fitzpatrick skin type I or II
  • Age 18 years or older

Exclusion criteria

for rosacea participants:

  • Unable or unwilling to provide written informed consent
  • Concomitant facial or medical condition that obscures diagnosis of rosacea (such as malar erythema from lupus erythematosus)
  • Acne vulgaris
  • Unable or unwilling to provide peripheral blood sample (a few teaspoons)
  • Inability for investigator to verify rosacea diagnosis on clinical examination due to rosacea treatment(s) leading to complete lack of signs and symptoms (such prior laser treatments, systemic tetracycline usage, etc.)
  • Use of topical prescription medications or procedures to the face within one month of enrollment
  • Women who are pregnant or lactating

Eligibility Criteria for Non-Rosacea Group:

Inclusion criteria

for control participants:

  • No history of rosacea
  • No clinical signs or symptoms of rosacea
  • No family history of rosacea
  • All four grandparents of European descent
  • Fitzpatrick skin type I or II
  • Age 18 years or older

Exclusion criteria

for control participants:

  • Unable or unwilling to provide written informed consent
  • Acne vulgaris
  • Unable or unwilling to provide peripheral blood sample (a few teaspoons)
  • Women who are pregnant or lactating
  • Use of topical prescription medications or procedures to the face within one month of enrollment
  • Skin conditions that might interfere with interpretation of procedure results (at the discretion of the investigator)

Treatment and study plan

buccal swab

Genetic

cheek swab for DNA sampling

Primary outcomes

  1. Targeted interrogation of alleles and assessment of rosacea co-morbidities.

    Time frame: Up to 2 years

Sponsors and collaborators

Lead sponsor

Stanford University

Other

Registry information

Official study title

Validation of Candidate Rosacea Genes By Targeted Interrogation of Alleles and Assessment of Rosacea Co-morbidities

Important dates

Study start
2012
Primary completion
2018
Study completion
2018
First posted
Jun 1, 2016
Registry last updated
Sep 26, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.